RecruitingPhase 3NCT05057468

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Cyclosporine As a Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Sponsor

Assiut University

Enrollment

30 participants

Start Date

Oct 20, 2021

Study Type

INTERVENTIONAL

Conditions

Primary Autoimmune Hemolytic Anemia

Summary

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cyclosporine and a drug called Rituximab for people with primary autoimmune hemolytic anemia. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCyclosporine

2.5-5 mg orally for 3 months

DRUGRituximab

375 mg/ m2 weekly dose for a maximum of 4 weeks

Locations(2)

Assiut university hospital

Asyut, Asyut Governorate, Egypt

Assiut university hospital

Asyut, Asyut Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05057468